Identifikation und Charakterisierung genetischer Risikofaktoren der Parkinson Erkrankung in der isländischen Bevölkerung

Die Identifizierung genetischer Varianten mit unterschiedlichster Effektstärke spielt bei der Erforschung komplexer und multifaktorieller Erkrankungen, wie der Parkinson Erkrankung, eine entscheidende Rolle. Seit dem letzten Jahrzehnt stehen hierfür die sogenannten genomweiten Assoziationsstudien zur Verfügung. Sie haben bereits einen erheblichen Beitrag zum Verständnis der Ätiologie dieser Erkrankungen beigetragen. Dennoch ist die genetische Variabilität in ihrer Gesamtheit bei weitem nicht erklärt und man ist weiter auf der Suche nach kausativen Varianten, die die „fehlende Erblichkeit“ erklären sollen. Die hier vorgestellte Arbeit baut auf das Gesamt-Genom-Sequenzierungs-Projekt des isländischen Pharmaunternehmens deCODE Genetics auf. Aufgrund der geografischen und kulturellen Eigenständigkeit dieser Population nimmt man eine geringere genetische Heterogenität an. Folglich eignet sich diese Inselbevölkerung sehr gut zur Erforschung komplexer Merkmale. Das Ziel war die Identifikation und Charakterisierung genetischer Risikofaktoren der Parkinson Erkrankung in der isländischen Bevölkerung. Hierbei wurde die Beteiligung des EIF4G1-Gens bei der Pathogenese der Parkinson Erkrankung weiter geklärt, sowie die Rolle heterozygoter CNVs im rezessiven PARK2-Gen. Die Aufschlüsselung der genetischen Architektur komplexer Erkrankungen und damit die Identifizierung und Charakterisierung von Risikovarianten ist von großer Bedeutung für die Prävention und Behandlung von Krankheiten. Darüber hinaus verbessert das Verständnis zugrundeliegender Vererbungsmuster und die Kenntnis von Suszeptibilitätsfaktoren auf Grund ihrer Effektstärke die molekulargenetische Diagnostik

Variant of TREM2 associated with the risk of Alzheimer's disease.

To access publisher's full text version of this article. Please click on the hyperlink in Additional Links field.BACKGROUND: Sequence variants, including the ε4 allele of apolipoprotein E, have been associated with the risk of the common late-onset form of Alzheimer's disease. Few rare variants affecting the risk of late-onset Alzheimer's disease have been found. METHODS: We obtained the genome sequences of 2261 Icelanders and identified sequence variants that were likely to affect protein function. We imputed these variants into the genomes of patients with Alzheimer's disease and control participants and then tested for an association with Alzheimer's disease. We performed replication tests using case-control series from the United States, Norway, The Netherlands, and Germany. We also tested for a genetic association with cognitive function in a population of unaffected elderly persons. RESULTS: A rare missense mutation (rs75932628-T) in the gene encoding the triggering receptor expressed on myeloid cells 2 (TREM2), which was predicted to result in an R47H substitution, was found to confer a significant risk of Alzheimer's disease in Iceland (odds ratio, 2.92; 95% confidence interval [CI], 2.09 to 4.09; P=3.42×10(-10)). The mutation had a frequency of 0.46% in controls 85 years of age or older. We observed the association in additional sample sets (odds ratio, 2.90; 95% CI, 2.16 to 3.91; P=2.1×10(-12) in combined discovery and replication samples). We also found that carriers of rs75932628-T between the ages of 80 and 100 years without Alzheimer's disease had poorer cognitive function than noncarriers (P=0.003). CONCLUSIONS: Our findings strongly implicate variant TREM2 in the pathogenesis of Alzheimer's disease. Given the reported antiinflammatory role of TREM2 in the brain, the R47H substitution may lead to an increased predisposition to Alzheimer's disease through impaired containment of inflammatory processes. (Funded by the National Institute on Aging and others.).Research Council of NorwayNational Institute on Aging P50-AG025688 U01AG006781South-Eastern Norway Health AuthorityNational Institutes of Health U01HG004438National Human Genome Research Institute U01HG004610eMERGE Administrative Coordinating Center U01HG004603National Center for Biotechnology InformationErasmus Medical CenterErasmus University, RotterdamNetherlands Organization for Health Research and DevelopmentResearch Institute for Diseases in the ElderlyMinistry of Education, Culture and ScienceMinistry for Health, Welfare and SportsMunicipality of RotterdamResearch Institute for Diseases in the Elderly 014-93-015Stichting Alzheimer Onder-zoekHersenstichting NederlandNetherlands Genomics Initiative-Netherlands Organization for Scientific Research (Center for Medical Systems Biology and the Netherlands Consortium for Healthy Aging)info:eu-repo/grantAgreement/EC/FP7/20141

EIF4G1 is neither a strong nor a common risk factor for Parkinson's disease: evidence from large European cohorts

BACKGROUND: Missense mutations in the eukaryotic translation initiation factor 4-gamma 1 (EIF4G1) gene have previously been implicated in familial Parkinson's disease (PD). A large PD family with autosomal-dominant segregation showed a heterozygous missense mutation and additional patients were found to have unique sequence variants that have not been observed in controls. Subsequent studies have reported contradictory findings. METHODS: We assessed the relevance of EIF4G1 mutations in a European cohort of 2146 PD patients. Of these, 2051 sporadic PD patients were screened for the reported p.Ala502Val and p.Arg1205His mutations. In addition, the complete coding region of EIF4G1 was directly sequenced in 95 familial PD patients with autosomal-dominant inheritance. Moreover, we imputed the p.Arg1205His substitution and tested for association with PD in the Icelandic population (93 698 samples). RESULTS: We did not observe the presence of the p.Ala502Val substitution in our cohort; however, the p.Arg1205His mutation was identified in one sporadic PD patient. The same mutation was also found in 76 Icelandic subjects older than 65 years using haplotype imputing. Only five of these subjects reported PD symptoms (OR 1.3, p=0.50). Thus, if causal, the p.Arg1205His EIF4G1 mutation has a low penetrance or a late onset manifestation. A novel variant p.Arg566Cys found in a patient with familial PD did not cosegregate with PD in all three affected siblings. All further recently published EIF4G1 mutations found in our cohort are likely to be benign polymorphisms. CONCLUSIONS: This is the largest genetic study of EIF4G1 mutations in PD. Our data do not support the EIF4G1 gene as a high-risk PD locus, neither for the familial nor the sporadic condition. Furthermore, the p.Arg1205His mutation is not significantly associated with increased risk of PD in the Icelandic population. Therefore, caution should be exercised when interpreting EIF4G1 genotyping results in isolated patients and PD families. In summary, diagnostic testing of EIF4G1 should not be recommended in clinical settings

A mutation in APP protects against Alzheimer's disease and age-related cognitive decline.

To access publisher full text version of this article. Please click on the hyperlink in Additional Links field.The prevalence of dementia in the Western world in people over the age of 60 has been estimated to be greater than 5%, about two-thirds of which are due to Alzheimer's disease. The age-specific prevalence of Alzheimer's disease nearly doubles every 5 years after age 65, leading to a prevalence of greater than 25% in those over the age of 90 (ref. 3). Here, to search for low-frequency variants in the amyloid-β precursor protein (APP) gene with a significant effect on the risk of Alzheimer's disease, we studied coding variants in APP in a set of whole-genome sequence data from 1,795 Icelanders. We found a coding mutation (A673T) in the APP gene that protects against Alzheimer's disease and cognitive decline in the elderly without Alzheimer's disease. This substitution is adjacent to the aspartyl protease β-site in APP, and results in an approximately 40% reduction in the formation of amyloidogenic peptides in vitro. The strong protective effect of the A673T substitution against Alzheimer's disease provides proof of principle for the hypothesis that reducing the β-cleavage of APP may protect against the disease. Furthermore, as the A673T allele also protects against cognitive decline in the elderly without Alzheimer's disease, the two may be mediated through the same or similar mechanisms.Lung GO Sequencing Project HL-102923 WHI Sequencing Project HL-102924 Broad GO Sequencing Project HL-102925 Seattle GO Sequencing Project HL-102926 Heart GO Sequencing Project HL-10301

Variant of TREM2 associated with the risk of Alzheimer's disease

Background: Sequence variants, including the ε4 allele of apolipoprotein E, have been associated with the risk of the common late-onset form of Alzheimer's disease. Few rare variants affecting the risk of late-onset Alzheimer's disease have been found. Methods: We obtained the genome sequences of 2261 Icelanders and identified sequence variants that were likely to affect protein function. We imputed these variants into the genomes of patients with Alzheimer's disease and control participants and then tested for an association with Alzheimer's disease. We performed replication tests using case-control series from the United States, Norway, the Netherlands, and Germany. We also tested for a genetic association with cognitive function in a population of unaffected elderly persons. Results: A rare missense mutation (rs75932628-T) in the gene encoding the triggering receptor expressed on myeloid cells 2 (TREM2), which was predicted to result in an R47H substitution, was found to confer a significant risk of Alzheimer's disease in Iceland (odds ratio, 2.92; 95% confidence interval [CI], 2.09 to 4.09; P = 3.42×10-10). The mutation had a frequency of 0.46% in controls 85 years of age or older. We observed the association in additional sample sets (odds ratio, 2.90; 95% CI, 2.16 to 3.91; P = 2.1×10-12 in combined discovery and replication samples). We also found that carriers of rs75932628-T between the ages of 80 and 100 years without Alzheimer's disease had poorer cognitive function than noncarriers (P = 0.003). Conclusions: Our findings strongly implicate variant TREM2 in the pathogenesis of Alzheimer's disease. Given the reported antiinflammatory role of TREM2 in the brain, the R47H substitution may lead to an increased predisposition to Alzheimer's disease through impaired containment of inflammatory processes. (Funded by the National Institute on Aging and others.) Copyrigh

Co-localisation of abnormal brain structure and function in specific language impairment

We assessed the relationship between brain structure and function in 10 individuals with specific language impairment (SLI), compared to six unaffected siblings, and 16 unrelated control participants with typical language. Voxel-based morphometry indicated that grey matter in the SLI group, relative to controls, was increased in the left inferior frontal cortex and decreased in the right caudate nucleus and superior temporal cortex bilaterally. The unaffected siblings also showed reduced grey matter in the caudate nucleus relative to controls. In an auditory covert naming task, the SLI group showed reduced activation in the left inferior frontal cortex, right putamen, and in the superior temporal cortex bilaterally. Despite spatially coincident structural and functional abnormalities in frontal and temporal areas, the relationships between structure and function in these regions were different. These findings suggest multiple structural and functional abnormalities in SLI that are differently associated with receptive and expressive language processing